In 2017, a supporter of ICAN told us that the clinical trials the FDA relied upon to license these vaccines only reviewed safety for a few days after injection. ICAN found th…
In 2017, a supporter of ICAN told us that the clinical trials the FDA relied upon to license these vaccines only reviewed safety for a few days after injection. ICAN found this claim incredible. It assumed the claim was likely false.
It seemed improbable because Congress mandated that the FDA only license drugs which have been proven to be “safe and effective” in a clinical trial, and five days of post-injection safety data would be patently insufficient to demonstrate safety. This is why drugs, such as Enbrel, Lipitor, Belviq, and Botox, typically given to adults, had safety review periods of 6.6 years, 4.8 years, 2 years, and 51 weeks respectively, and each was tested against a placebo control group. The FDA even states that the clinical trial relied upon for licensure is typically “1 to 4 years” in duration.
If anything, the safety review period in a clinical trial for a vaccine given to babies and toddlers should be longer since autoimmune, neurological, and developmental disorders will often not be diagnosed until after babies are at least a few years old.
Hi Tessa, I came across this new old info___:
ICAN FILES FORMAL PETITION DEMANDING THAT THE FDA WITHDRAW ITS LICENSURE OF HEPATITIS B VACCINES
https://icandecide.org/press-release/ican-files-formal-petition-demanding-that-the-fda-withdraw-its-licensure-of-hepatitis-b-vaccines-2/
In 2017, a supporter of ICAN told us that the clinical trials the FDA relied upon to license these vaccines only reviewed safety for a few days after injection. ICAN found this claim incredible. It assumed the claim was likely false.
It seemed improbable because Congress mandated that the FDA only license drugs which have been proven to be “safe and effective” in a clinical trial, and five days of post-injection safety data would be patently insufficient to demonstrate safety. This is why drugs, such as Enbrel, Lipitor, Belviq, and Botox, typically given to adults, had safety review periods of 6.6 years, 4.8 years, 2 years, and 51 weeks respectively, and each was tested against a placebo control group. The FDA even states that the clinical trial relied upon for licensure is typically “1 to 4 years” in duration.
If anything, the safety review period in a clinical trial for a vaccine given to babies and toddlers should be longer since autoimmune, neurological, and developmental disorders will often not be diagnosed until after babies are at least a few years old.